Drug intelligence / Profile preview

coenzyme A + abiraterone

Development stage: Unknown
Lead developer: Jiangnan University
Modality: Small Molecules
Administration: Oral

Overview

A combination therapy consisting of coenzyme A (CoA), a regulatory metabolic compound, and abiraterone, an antiandrogen medication. This combination is being investigated for the treatment of castration-resistant prostate cancer (CRPC). Abiraterone works by inhibiting CYP17A1, reducing androgen production in the body, while coenzyme A is a metabolic compound that may enhance therapeutic effects when combined with abiraterone.

Targets

3β-HSD (3β-Hydroxysteroid Dehydrogenase/Δ5-4 isomerase type 1)AR (Adrenergic receptors)CYP17A1 (Steroid 17-alpha-hydroxylase/C17,20 lyase)

Beyond the preview

Go deeper on coenzyme A + abiraterone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on coenzyme A + abiraterone.

Explore the full profile